Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape

Research Articles
Written By Knapsack

from National Library of Medicine

Timely detection of the pathophysiological changes and cognitive impairment caused by Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker-guided targeted therapies that may be most effective when provided early in the disease.

Knapsack http://www.knapsackcreative.com
Previous

Direct-to-Consumer Alzheimer’s Blood Test Opens Pandora’s Box
Next

BBM Workgroup Presentation at Alzheimer’s Association International Conference 2023